PROCEPT BIOROBOTICS:TRANSFORMING THE BPH TREATMENT LANDSCAPE $PRCT
Excited to share an article about Procept BioRobotics Corporation (NASDAQ: PRCT), a surgical robotics company focused on developing innovative solutions in urology to advance patient care. The Company has developed a highly successful proprietary technology to meet the needs of a large population of patients with benign prostatic hyperplasia (BPH).
For Q3FY23, Procept reported total revenue of $35.1 million, a 72% increase compared to the previous quarter. For the full fiscal year 2023, Procept expects revenues of approximately $133.5 million, which represents a growth of 78% over the previous year, with a gross margin of about 55%. The Company's revenue is expected to continue growing, making it a noteworthy Company to keep an eye on.
Read on to know more:
https://www.aviseanalytics.com/procept-biorobotics-transforming-the-bph-treatment-landscape/